Aprea Therapeutics, Inc. — Form 8-K Summary
Reporting date: March 13, 2023. The filing reports a material liquidity and banking update following the FDIC’s takeover of Silicon Valley Bank (SVB) on March 10, 2023.
Business Context and Reporting Period
Aprea Therapeutics is a biotechnology company. This Form 8-K was furnished under Item 7.01, Regulation FD Disclosure, and does not provide quarterly or annual operating results. No revenue, earnings, cash-flow statement, margin, debt, or broader liquidity metrics were reported.
Cash, Liquidity, and Key Financial Metrics
- The Company reported approximately $1.5 million in cash deposits at SVB.
- The Company also reported approximately $28.9 million invested in a money market mutual fund purchased through SVB but managed by a third-party asset manager.
- Management believes the money market mutual fund assets belong to the Company and are not bank deposits.
- The Company expects to have access to the full money market fund balance, but stated that the timing and process for accessing those funds were unclear as of the filing date.
- The filing does not provide total cash, cash equivalents, debt, current liabilities, revenue, profit, operating cash flow, or cash runway.
Material Changes, Outlook, and Risks
The principal development was the potential temporary restriction on access to funds held at or through SVB. The Company cited risks relating to its ability and timing to access both the SVB deposit and the money market mutual fund. It also noted general risks concerning clinical trials, study results, regulatory submissions, financial performance, geopolitical conditions, economic and competitive factors, and other risks disclosed in its SEC filings.
The filing contains no specific financial guidance or revised clinical-development timetable. Forward-looking statements reflect management’s expectations as of the filing date, and the Company stated that it had no obligation to update them publicly.
Important Facts for Investors to Verify
- Whether the approximately $1.5 million SVB deposit was fully accessible under the joint Treasury, Federal Reserve, and FDIC announcement.
- The timing and operational process for accessing the approximately $28.9 million money market mutual fund.
- Whether the fund’s assets were legally segregated from SVB deposits and remained available without material loss or delay.
- Aprea’s total cash balance, quarterly cash burn, debt obligations, and projected cash runway in subsequent SEC filings.
- Any effect of the banking disruption on clinical programs, vendors, payroll, or other operating activities.